文献速递胸部肿瘤

克唑替尼在不同ROS1融合伴侣类型ROS1重排NSCLC中的疗效

Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2018-04-25

该单中心回顾性研究纳入49例接受克唑替尼治疗的ROS1重排NSCLC患者,36例可评估融合伴侣,其中19例为CD74-ROS1。CD74-ROS1组治疗前脑转移率更高(6例对0例,p=0.020),非CD74-ROS1组客观缓解率94.11%对73.68%,中位无进展生存期17.63个月对12.63个月(p=0.048),中位总生存期44.50个月对24.33个月(p=0.036)。

要点

  • CD74-ROS1融合患者治疗前脑转移率更高(6例对0例,p=0.020)。
  • 非CD74-ROS1组客观缓解率94.11%,CD74-ROS1组73.68%。
  • 非CD74-ROS1组PFS和OS均显著更长(p=0.048和p=0.036)。

核心结论

  • CD74-ROS1融合伴侣患者更易出现脑转移,非CD74-ROS1组接受克唑替尼治疗有生存改善趋势但非独立显著。

研究设计与样本

  • 单中心回顾性研究,纳入2014年4月至2016年12月接受克唑替尼治疗的49例ROS1重排NSCLC患者,36例有肿瘤组织可评估融合伴侣。

主要发现

  • 36例可评估患者中19例为CD74-ROS1融合。
  • CD74-ROS1组治疗前脑转移6例,非CD74-ROS1组0例(p=0.020)。
  • 全部患者客观缓解率83.3%,非CD74-ROS1组94.11%,CD74-ROS1组73.68%。
  • 非CD74-ROS1组中位无进展生存期17.63个月对12.63个月(p=0.048),中位总生存期44.50个月对24.33个月(p=0.036)。
  • 多变量分析中仅治疗前脑转移与总生存期相关(p=0.010),无因素与无进展生存期显著相关。

临床怎么用

  • 对ROS1重排NSCLC患者可考虑评估ROS1融合伴侣类型以辅助预后判断。
  • CD74-ROS1融合患者应关注脑转移筛查。

局限性

  • 单中心回顾性研究,样本量有限。
  • 仅36例患者有肿瘤组织可评估融合伴侣。
  • 融合伴侣与生存的关联在多变量分析中未达独立显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: ROS1 rearrangement-positive NSCLC can be treated effectively with an anaplastic lymphoma kinase/ROS1/mesenchymal-epithelial transition factor inhibitor such as crizotinib; however, the rate of response remains variable. Although several ROS1 fusion partners have been identified, the efficacy of crizotinib in patients with different types of ROS1 fusion partners is poorly understood. METHODS: We reviewed clinicopathological data of patients with ROS1 rearrangement who received crizotinib therapy at our institution between April 2014 and December 2016. ROS1 fusion partners were evaluated by using Sanger sequencing for available tumor tissue. RESULTS: During the study, 49 patients were found to have ROS1 rearrangement and were subsequently treated with crizotinib. Tumor specimens were available for 36 patients, of whom 19 were found to have CD 74 molecule gene (CD74)-ROS1 fusion partners. Before therapy, those in the CD74-ROS1 group were found to have a higher rate of brain metastases (six versus 0 [p = 0.020]). The objective response rate for crizotinib was 83.3% in all patients, whereas it was 94.11% and 73.68% in the non-CD74-ROS1 and CD74-ROS1 groups, respectively. As compared with the CD74-ROS1 group, the non-CD74-ROS1 group had both a significantly longer progression-free survival (17.63 months versus 12.63 months [p = 0.048]) and a significantly longer overall survival (44.50 months versus 24.33 months [p = 0.036]). On multivariable analysis, the only factor associated with overall survival was presence of brain metastases before therapy (p = 0.010). There were no significant factors associated with progression-free survival in the multivariable analysis. CONCLUSIONS: These findings suggests that patients with CD74-ROS1 fusion partners are more likely to present with brain metastases. Although not independently significant, a trend toward improved survival was observed in patients in the non-CD74-ROS1 group when they were treated with crizotinib.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Li Z, Shen L, Ding D, et al. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2018. PMID: 29704675. doi:10.1016/j.jtho.2018.04.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。